Summary of Reports of Incidence of TEL/AML1Fusion in Relapsed Patients
| Author . | Type of Analysis . | Rx Reg. . | All Pts . | Relapsed B-Cell Pts . | TA+ (%) . | TA Pts at Rel. 1 . | TA Pts at Rel. 2 . |
|---|---|---|---|---|---|---|---|
| Nakao7 | R | CCLSG | 19 | 16 | 3 (19%) | 3 | 0 |
| Satake19 | R | Tokyo CCSG | 7 | 7 | 2 (28%) | 2 | 0 |
| Tokai CCSG | |||||||
| CCLSG | |||||||
| Harbott17 | R | BFM-86 | 46 | 35 | 9 (26%) | 5 | 4 |
| BFM-90 | |||||||
| Co-ALL05-92 | |||||||
| Seeger18 | R | ALL-REZBFM* | 146 | 133 | 32 (24%) | 27 | 5 |
| Author . | Type of Analysis . | Rx Reg. . | All Pts . | Relapsed B-Cell Pts . | TA+ (%) . | TA Pts at Rel. 1 . | TA Pts at Rel. 2 . |
|---|---|---|---|---|---|---|---|
| Nakao7 | R | CCLSG | 19 | 16 | 3 (19%) | 3 | 0 |
| Satake19 | R | Tokyo CCSG | 7 | 7 | 2 (28%) | 2 | 0 |
| Tokai CCSG | |||||||
| CCLSG | |||||||
| Harbott17 | R | BFM-86 | 46 | 35 | 9 (26%) | 5 | 4 |
| BFM-90 | |||||||
| Co-ALL05-92 | |||||||
| Seeger18 | R | ALL-REZBFM* | 146 | 133 | 32 (24%) | 27 | 5 |
Review of published reports assessing the incidence ofTEL/AML1 rearrangement in relapsed patients.
Abbreviations: R, retrospective; Rx reg., treatment regimen; pts, patients; TA+, TEL/AML1-positive; TA−,TEL/AML1-negative; Rel., relapse; CCLSG, Children’s Cancer and Leukemia Study Group, Japan; BFM, Berlin-Frankfurt-Muenster; ALL-REZ-BFM, ALL relapse protocol for the BFM.
Therapy received at relapse. Initial therapy consisted of unspecified BFM or Co-ALL protocols.